Connor, Clark & Lunn Investment Management (CC&L)’s Protalix BioTherapeutics PLX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$450K	Sell	207,275 -24,818	-11%	-$61.6K	﹤0.01%	1333
2025 Q4	$418K	Sell	232,093 -168,305	-42%	-$344K	﹤0.01%	1334
2025 Q3	$889K	Sell	400,398 -95,818	-19%	-$156K	﹤0.01%	1096
2025 Q2	$734K	Buy	496,216 +13,341	+3%	+$27.3K	﹤0.01%	1142
2025 Q1	$1.24M	Buy	+482,875	New	+$1.15M	0.01%	882
2024 Q1	–	Sell	-70,990	Closed	-$126K	–	1677
2023 Q4	$126K	Sell	70,990 -96,546	-58%	-$150K	﹤0.01%	1301
2023 Q3	$278K	Buy	167,536 +51,997	+45%	+$93.3K	﹤0.01%	1161
2023 Q2	$231K	Sell	115,539 -43,164	-27%	-$103K	﹤0.01%	1160
2023 Q1	$333K	Buy	+158,703	New	+$278K	﹤0.01%	988
2016 Q4	–	Sell	-5,070	Closed	-$29K	–	963
2016 Q3	$29K	Hold	5,070	–	–	﹤0.01%	817
2016 Q2	$32K	Sell	5,070 -60	-1%	-$479	﹤0.01%	846
2016 Q1	$43K	Hold	5,130	–	–	﹤0.01%	803
2015 Q4	$52K	Buy	5,130 +1,340	+35%	+$13.6K	﹤0.01%	784
2015 Q3	$45K	Buy	3,790 +2,010	+113%	+$31.9K	﹤0.01%	693
2015 Q2	$35K	Buy	+1,780	New	+$36.9K	﹤0.01%	613
2013 Q4	–	Sell	-5,050	Closed	-$235K	–	750
2013 Q3	$235K	Buy	5,050 +540	+12%	+$27.7K	﹤0.01%	446
2013 Q2	$234K	Buy	+4,510	New	+$239K	﹤0.01%	457